Pelvic Exenteration Affords Safe and Durable Treatment for Locally Advanced Rectal Carcinoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-04-04

AUTHORS

Christopher J. Gannon, Jonathan S. Zager, George J. Chang, Barry W. Feig, Christopher G. Wood, John M. Skibber, Miguel A. Rodriguez-Bigas

ABSTRACT

BackgroundTreatment of locally advanced rectal carcinoma (LARC) often involves exenterative surgery, which can be associated with high perioperative morbidity and mortality. To assist in patient selection for radical surgery, we sought to determine clinicopathologic factors influencing recurrence and disease-free survival (DFS) of LARC.MethodsConsecutive patients with LARC undergoing exenterative surgery were retrospectively identified in our institutional database. Factors evaluated included age, sex, primary versus recurrent tumors, neoadjuvant or adjuvant chemoradiotherapy, resection margin status, recurrence, time to recurrence, and survival. The primary outcome was DFS. Secondary outcomes were overall survival and perioperative morbidity.ResultsA total of 72 patients were identified; median age was 52 years, and median follow-up time was 30 months. The overall complication rate was 43%; rates were similar among the patients with primary (47%) or recurrent (37%) LARC. Primary or recurrent tumor status was the only factor significantly predictive of outcome after exenteration. Local recurrence rates were lower in the primary group (primary 22%, recurrent 52%, P = .05). A significant difference in 5-year DFS was found between primary and recurrent tumor (52% vs. 13%; P < .01). The median time to recurrence was longer in the patients with primary LARC (17 months vs. 8 months; P < .01).ConclusionsThe complication rates for pelvic exenteration remain high, but the morbidity can typically be managed without a clinically important increase in hospitalization. In primary LARC, an aggressive surgical approach provides most patients 5-year DFS. Select patients with recurrent LARC will also benefit from pelvic exenteration. More... »

PAGES

1870-1877

Identifiers

URI

http://scigraph.springernature.com/pub.10.1245/s10434-007-9385-9

DOI

http://dx.doi.org/10.1245/s10434-007-9385-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1006388680

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17406945


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Age Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Selection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pelvic Exenteration", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postoperative Complications", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Safety", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sex Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gannon", 
        "givenName": "Christopher J.", 
        "id": "sg:person.01242527567.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242527567.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zager", 
        "givenName": "Jonathan S.", 
        "id": "sg:person.0655141244.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655141244.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chang", 
        "givenName": "George J.", 
        "id": "sg:person.0640201363.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640201363.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feig", 
        "givenName": "Barry W.", 
        "id": "sg:person.0634233332.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634233332.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Unit 1373, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, Unit 1373, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wood", 
        "givenName": "Christopher G.", 
        "id": "sg:person.01040121722.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Skibber", 
        "givenName": "John M.", 
        "id": "sg:person.0607410203.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607410203.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rodriguez-Bigas", 
        "givenName": "Miguel A.", 
        "id": "sg:person.0743471123.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743471123.04"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1245/aso.2004.06.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033196228", 
          "https://doi.org/10.1245/aso.2004.06.010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10434-999-0171-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035986580", 
          "https://doi.org/10.1007/s10434-999-0171-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-04-04", 
    "datePublishedReg": "2007-04-04", 
    "description": "BackgroundTreatment of locally advanced rectal carcinoma (LARC) often involves exenterative surgery, which can be associated with high perioperative morbidity and mortality. To assist in patient selection for radical surgery, we sought to determine clinicopathologic factors influencing recurrence and disease-free survival (DFS) of LARC.MethodsConsecutive patients with LARC undergoing exenterative surgery were retrospectively identified in our institutional database. Factors evaluated included age, sex, primary versus recurrent tumors, neoadjuvant or adjuvant chemoradiotherapy, resection margin status, recurrence, time to recurrence, and survival. The primary outcome was DFS. Secondary outcomes were overall survival and perioperative morbidity.ResultsA total of 72 patients were identified; median age was 52 years, and median follow-up time was 30 months. The overall complication rate was 43%; rates were similar among the patients with primary (47%) or recurrent (37%) LARC. Primary or recurrent tumor status was the only factor significantly predictive of outcome after exenteration. Local recurrence rates were lower in the primary group (primary 22%, recurrent 52%, P\u00a0=\u00a0.05). A significant difference in 5-year DFS was found between primary and recurrent tumor (52% vs. 13%; P\u00a0<\u00a0.01). The median time to recurrence was longer in the patients with primary LARC (17 months vs. 8 months; P\u00a0<\u00a0.01).ConclusionsThe complication rates for pelvic exenteration remain high, but the morbidity can typically be managed without a clinically important increase in hospitalization. In primary LARC, an aggressive surgical approach provides most patients 5-year DFS. Select patients with recurrent LARC will also benefit from pelvic exenteration.", 
    "genre": "article", 
    "id": "sg:pub.10.1245/s10434-007-9385-9", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1105545", 
        "issn": [
          "1068-9265", 
          "1534-4681"
        ], 
        "name": "Annals of Surgical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "keywords": [
      "disease-free survival", 
      "advanced rectal carcinoma", 
      "exenterative surgery", 
      "perioperative morbidity", 
      "complication rate", 
      "pelvic exenteration", 
      "recurrent tumors", 
      "rectal carcinoma", 
      "high perioperative morbidity", 
      "recurrent tumor status", 
      "ConclusionsThe complication rates", 
      "overall complication rate", 
      "aggressive surgical approach", 
      "resection margin status", 
      "local recurrence rate", 
      "adjuvant chemoradiotherapy", 
      "median follow", 
      "radical surgery", 
      "MethodsConsecutive patients", 
      "Secondary outcomes", 
      "clinicopathologic factors", 
      "margin status", 
      "primary outcome", 
      "overall survival", 
      "median age", 
      "most patients", 
      "median time", 
      "patient selection", 
      "ResultsA total", 
      "recurrence rate", 
      "institutional database", 
      "surgical approach", 
      "durable treatment", 
      "tumor status", 
      "patients", 
      "recurrence", 
      "morbidity", 
      "LARC", 
      "exenteration", 
      "surgery", 
      "only factor", 
      "significant differences", 
      "carcinoma", 
      "survival", 
      "tumors", 
      "outcomes", 
      "primary group", 
      "age", 
      "status", 
      "BackgroundTreatment", 
      "chemoradiotherapy", 
      "hospitalization", 
      "follow", 
      "mortality", 
      "factors", 
      "months", 
      "important increase", 
      "rate", 
      "sex", 
      "treatment", 
      "total", 
      "group", 
      "years", 
      "time", 
      "differences", 
      "database", 
      "increase", 
      "selection", 
      "approach", 
      "affords"
    ], 
    "name": "Pelvic Exenteration Affords Safe and Durable Treatment for Locally Advanced Rectal Carcinoma", 
    "pagination": "1870-1877", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1006388680"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1245/s10434-007-9385-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17406945"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1245/s10434-007-9385-9", 
      "https://app.dimensions.ai/details/publication/pub.1006388680"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_452.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1245/s10434-007-9385-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1245/s10434-007-9385-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1245/s10434-007-9385-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1245/s10434-007-9385-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1245/s10434-007-9385-9'


 

This table displays all metadata directly associated to this object as RDF triples.

283 TRIPLES      21 PREDICATES      122 URIs      112 LITERALS      32 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1245/s10434-007-9385-9 schema:about N00b8f7e4d20b4ef287e297cc20e5d8c6
2 N01b47fb68cac4a3791c20c37232081d6
3 N0b7cb01da0744573950710e0e58305e2
4 N0c6293f78b8d49df97147f50ada07f64
5 N1609bb620f64498b9ca22883c22e737f
6 N1a349d0e95644c049ae3bc8e12729cc6
7 N2048ac51dc4f4683bed377098c2c615c
8 N27a597a6e8d24c3699974be5a4bf7299
9 N40f336571a1c48819b762c3d01b3a18b
10 N45907743e8be4858bb17a24fc605cb74
11 N4d07cbe650bf4234b3752fd437ad553d
12 N53e6eb8703514cdfad694eb77c411b6f
13 N5d356971089b4cf19a1156abf4b3afd7
14 N788fdc5904344f63805f36e67e7a309b
15 N8c3c047a773a40a7a794295c78e45811
16 N995c7c9485df4affb8510218776b66d0
17 N9b7d480363104f83b81481a9eb6224e7
18 Na66192c4a6454f58a0a3809f0ff08ede
19 Naf4e80ecfbd04cb5ab7b60b6fac0275f
20 Nb3d0f310183244e497eae74c76d5fcb4
21 Nc691af260f624a7ebcaf3c64725e355f
22 Nc6995e963d0443bda82c419a8012c7f3
23 Nd28c50d138f84c8497c85c49b4968c3a
24 Nd441e2605f2b401bb25f7591adca01c5
25 Ne58a805fe95a4629ba3d2a7840454020
26 anzsrc-for:11
27 anzsrc-for:1103
28 schema:author N1726b9cd6f514dbbabe93c536951be70
29 schema:citation sg:pub.10.1007/s10434-999-0171-8
30 sg:pub.10.1245/aso.2004.06.010
31 schema:datePublished 2007-04-04
32 schema:datePublishedReg 2007-04-04
33 schema:description BackgroundTreatment of locally advanced rectal carcinoma (LARC) often involves exenterative surgery, which can be associated with high perioperative morbidity and mortality. To assist in patient selection for radical surgery, we sought to determine clinicopathologic factors influencing recurrence and disease-free survival (DFS) of LARC.MethodsConsecutive patients with LARC undergoing exenterative surgery were retrospectively identified in our institutional database. Factors evaluated included age, sex, primary versus recurrent tumors, neoadjuvant or adjuvant chemoradiotherapy, resection margin status, recurrence, time to recurrence, and survival. The primary outcome was DFS. Secondary outcomes were overall survival and perioperative morbidity.ResultsA total of 72 patients were identified; median age was 52 years, and median follow-up time was 30 months. The overall complication rate was 43%; rates were similar among the patients with primary (47%) or recurrent (37%) LARC. Primary or recurrent tumor status was the only factor significantly predictive of outcome after exenteration. Local recurrence rates were lower in the primary group (primary 22%, recurrent 52%, P = .05). A significant difference in 5-year DFS was found between primary and recurrent tumor (52% vs. 13%; P < .01). The median time to recurrence was longer in the patients with primary LARC (17 months vs. 8 months; P < .01).ConclusionsThe complication rates for pelvic exenteration remain high, but the morbidity can typically be managed without a clinically important increase in hospitalization. In primary LARC, an aggressive surgical approach provides most patients 5-year DFS. Select patients with recurrent LARC will also benefit from pelvic exenteration.
34 schema:genre article
35 schema:isAccessibleForFree false
36 schema:isPartOf N74b03dbe22c345bda6eca03190f227a5
37 Nf1047745b39c43fca7603b7bc1c2bc04
38 sg:journal.1105545
39 schema:keywords BackgroundTreatment
40 ConclusionsThe complication rates
41 LARC
42 MethodsConsecutive patients
43 ResultsA total
44 Secondary outcomes
45 adjuvant chemoradiotherapy
46 advanced rectal carcinoma
47 affords
48 age
49 aggressive surgical approach
50 approach
51 carcinoma
52 chemoradiotherapy
53 clinicopathologic factors
54 complication rate
55 database
56 differences
57 disease-free survival
58 durable treatment
59 exenteration
60 exenterative surgery
61 factors
62 follow
63 group
64 high perioperative morbidity
65 hospitalization
66 important increase
67 increase
68 institutional database
69 local recurrence rate
70 margin status
71 median age
72 median follow
73 median time
74 months
75 morbidity
76 mortality
77 most patients
78 only factor
79 outcomes
80 overall complication rate
81 overall survival
82 patient selection
83 patients
84 pelvic exenteration
85 perioperative morbidity
86 primary group
87 primary outcome
88 radical surgery
89 rate
90 rectal carcinoma
91 recurrence
92 recurrence rate
93 recurrent tumor status
94 recurrent tumors
95 resection margin status
96 selection
97 sex
98 significant differences
99 status
100 surgery
101 surgical approach
102 survival
103 time
104 total
105 treatment
106 tumor status
107 tumors
108 years
109 schema:name Pelvic Exenteration Affords Safe and Durable Treatment for Locally Advanced Rectal Carcinoma
110 schema:pagination 1870-1877
111 schema:productId N3f4a40731588412da7395ec08b3acc7d
112 N461c85291a8041eebdcf44e9ce222268
113 N509307c635c44206ab77c7a845a9011d
114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006388680
115 https://doi.org/10.1245/s10434-007-9385-9
116 schema:sdDatePublished 2022-10-01T06:34
117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
118 schema:sdPublisher Ne1af56e955814e6386e524fd6eabdf8e
119 schema:url https://doi.org/10.1245/s10434-007-9385-9
120 sgo:license sg:explorer/license/
121 sgo:sdDataset articles
122 rdf:type schema:ScholarlyArticle
123 N00b8f7e4d20b4ef287e297cc20e5d8c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Neoplasm Staging
125 rdf:type schema:DefinedTerm
126 N01b47fb68cac4a3791c20c37232081d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Radiotherapy, Adjuvant
128 rdf:type schema:DefinedTerm
129 N0b7cb01da0744573950710e0e58305e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Treatment Outcome
131 rdf:type schema:DefinedTerm
132 N0c6293f78b8d49df97147f50ada07f64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Disease-Free Survival
134 rdf:type schema:DefinedTerm
135 N1609bb620f64498b9ca22883c22e737f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Middle Aged
137 rdf:type schema:DefinedTerm
138 N1726b9cd6f514dbbabe93c536951be70 rdf:first sg:person.01242527567.45
139 rdf:rest Nf98b47e980374520ab76896e683e400f
140 N1a349d0e95644c049ae3bc8e12729cc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Neoplasm Recurrence, Local
142 rdf:type schema:DefinedTerm
143 N1f80a615c4a94084b275f29e2fc1bd1c rdf:first sg:person.0607410203.08
144 rdf:rest Nd6d648590b9f46dcb553bf7a4a884309
145 N2048ac51dc4f4683bed377098c2c615c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Humans
147 rdf:type schema:DefinedTerm
148 N27a597a6e8d24c3699974be5a4bf7299 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Follow-Up Studies
150 rdf:type schema:DefinedTerm
151 N3f4a40731588412da7395ec08b3acc7d schema:name doi
152 schema:value 10.1245/s10434-007-9385-9
153 rdf:type schema:PropertyValue
154 N40f336571a1c48819b762c3d01b3a18b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Aged
156 rdf:type schema:DefinedTerm
157 N45907743e8be4858bb17a24fc605cb74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Carcinoma
159 rdf:type schema:DefinedTerm
160 N461c85291a8041eebdcf44e9ce222268 schema:name pubmed_id
161 schema:value 17406945
162 rdf:type schema:PropertyValue
163 N4d07cbe650bf4234b3752fd437ad553d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Time Factors
165 rdf:type schema:DefinedTerm
166 N509307c635c44206ab77c7a845a9011d schema:name dimensions_id
167 schema:value pub.1006388680
168 rdf:type schema:PropertyValue
169 N53e6eb8703514cdfad694eb77c411b6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Adult
171 rdf:type schema:DefinedTerm
172 N5d356971089b4cf19a1156abf4b3afd7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Survival Rate
174 rdf:type schema:DefinedTerm
175 N74b03dbe22c345bda6eca03190f227a5 schema:issueNumber 6
176 rdf:type schema:PublicationIssue
177 N788fdc5904344f63805f36e67e7a309b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Neoadjuvant Therapy
179 rdf:type schema:DefinedTerm
180 N8c3c047a773a40a7a794295c78e45811 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Pelvic Exenteration
182 rdf:type schema:DefinedTerm
183 N995c7c9485df4affb8510218776b66d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Retrospective Studies
185 rdf:type schema:DefinedTerm
186 N9b7d480363104f83b81481a9eb6224e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Patient Selection
188 rdf:type schema:DefinedTerm
189 N9fd26104e79a431f8f941d34f440cb6d rdf:first sg:person.0640201363.83
190 rdf:rest Nec63a47870a546b18569250f58f47368
191 Na66192c4a6454f58a0a3809f0ff08ede schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Male
193 rdf:type schema:DefinedTerm
194 Na8fdcdcfbe394a58961ac40ae6b4d4f3 rdf:first sg:person.01040121722.56
195 rdf:rest N1f80a615c4a94084b275f29e2fc1bd1c
196 Naf4e80ecfbd04cb5ab7b60b6fac0275f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Chemotherapy, Adjuvant
198 rdf:type schema:DefinedTerm
199 Nb3d0f310183244e497eae74c76d5fcb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Rectal Neoplasms
201 rdf:type schema:DefinedTerm
202 Nc691af260f624a7ebcaf3c64725e355f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Female
204 rdf:type schema:DefinedTerm
205 Nc6995e963d0443bda82c419a8012c7f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Safety
207 rdf:type schema:DefinedTerm
208 Nd28c50d138f84c8497c85c49b4968c3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Sex Factors
210 rdf:type schema:DefinedTerm
211 Nd441e2605f2b401bb25f7591adca01c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Age Factors
213 rdf:type schema:DefinedTerm
214 Nd6d648590b9f46dcb553bf7a4a884309 rdf:first sg:person.0743471123.04
215 rdf:rest rdf:nil
216 Ne1af56e955814e6386e524fd6eabdf8e schema:name Springer Nature - SN SciGraph project
217 rdf:type schema:Organization
218 Ne58a805fe95a4629ba3d2a7840454020 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Postoperative Complications
220 rdf:type schema:DefinedTerm
221 Nec63a47870a546b18569250f58f47368 rdf:first sg:person.0634233332.35
222 rdf:rest Na8fdcdcfbe394a58961ac40ae6b4d4f3
223 Nf1047745b39c43fca7603b7bc1c2bc04 schema:volumeNumber 14
224 rdf:type schema:PublicationVolume
225 Nf98b47e980374520ab76896e683e400f rdf:first sg:person.0655141244.48
226 rdf:rest N9fd26104e79a431f8f941d34f440cb6d
227 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
228 schema:name Medical and Health Sciences
229 rdf:type schema:DefinedTerm
230 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
231 schema:name Clinical Sciences
232 rdf:type schema:DefinedTerm
233 sg:journal.1105545 schema:issn 1068-9265
234 1534-4681
235 schema:name Annals of Surgical Oncology
236 schema:publisher Springer Nature
237 rdf:type schema:Periodical
238 sg:person.01040121722.56 schema:affiliation grid-institutes:grid.240145.6
239 schema:familyName Wood
240 schema:givenName Christopher G.
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56
242 rdf:type schema:Person
243 sg:person.01242527567.45 schema:affiliation grid-institutes:grid.240145.6
244 schema:familyName Gannon
245 schema:givenName Christopher J.
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242527567.45
247 rdf:type schema:Person
248 sg:person.0607410203.08 schema:affiliation grid-institutes:grid.240145.6
249 schema:familyName Skibber
250 schema:givenName John M.
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607410203.08
252 rdf:type schema:Person
253 sg:person.0634233332.35 schema:affiliation grid-institutes:grid.240145.6
254 schema:familyName Feig
255 schema:givenName Barry W.
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634233332.35
257 rdf:type schema:Person
258 sg:person.0640201363.83 schema:affiliation grid-institutes:grid.240145.6
259 schema:familyName Chang
260 schema:givenName George J.
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640201363.83
262 rdf:type schema:Person
263 sg:person.0655141244.48 schema:affiliation grid-institutes:grid.240145.6
264 schema:familyName Zager
265 schema:givenName Jonathan S.
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655141244.48
267 rdf:type schema:Person
268 sg:person.0743471123.04 schema:affiliation grid-institutes:grid.240145.6
269 schema:familyName Rodriguez-Bigas
270 schema:givenName Miguel A.
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743471123.04
272 rdf:type schema:Person
273 sg:pub.10.1007/s10434-999-0171-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035986580
274 https://doi.org/10.1007/s10434-999-0171-8
275 rdf:type schema:CreativeWork
276 sg:pub.10.1245/aso.2004.06.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033196228
277 https://doi.org/10.1245/aso.2004.06.010
278 rdf:type schema:CreativeWork
279 grid-institutes:grid.240145.6 schema:alternateName Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA
280 Department of Urology, Unit 1373, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA
281 schema:name Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA
282 Department of Urology, Unit 1373, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA
283 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...